Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported long-term clinical study results from its NX-1207 Phase II prostate cancer trial NX03-0040. The new findings reflect statistically significant better results at up to 2.8 years for “NX-1207” treated patients as compared to controls. The study included 146 enrollments suffering with low-grade localized prostate cancer. The study was carried out at 44 U.S. investigational locations.
The study
In the trial, Nymox conducted a controlled comparison of patients who needed and received radiation and surgery cure for their cancer. They were based on blinded after treatment upgraded assessments of their pre-treatment. The trial concluded that after up to 2.8 years for single-injection of NX-1207 treated enrollments, there was a 68.2% reduction. The new trial also concluded that all instances of radiation or surgery, including elective cases dropped by 62.7% in NX-1207 enrollments against the randomized control group. The long-term result is a vital measure of drug treatment efficacy.
The management speaks
Paul Averback MD, the CEO of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) stated that these new results reflect the potential of NX-1207 to treat people with low-grade prostate cancer. It provides a tangible advantage in terms of avoidance of surgery and/or radiation and the associated side effects, risks and discomforts. The results indicate a considerable positive impact from a single painless injection.
The profile
To date, Nymox’s NX-1207 reflected an excellent safety profile. It showed safety in nine clinical studies of prostate and BPH cancer including repeat injection trials. The drug candidate does not result in immune responses like antibody formation. All these can cause drastic drug toxicity and limited usage to single treatments. NX-1207 treatment has shown to have no major adverse effect after treatment on testosterone levels or sexual function. Prostate cancer is one of the most commonly seen cancers in men, and is second major factor of cancer death in men.
